Vitamin D and diabetic nephropathy

Current Diabetes Reports

Volumn 8, Issue 6, 2008, Pages 464-469

  Li, Yan Chun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 7 DEHYDROCHOLESTEROL; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CALCITRIOL; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; FREE RADICAL; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN; PARICALCITOL; PROTEIN KINASE C; RENIN INHIBITOR; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMIN RECEPTOR;

ALBUMINURIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME GLYCOSYLATION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HYDROXYLATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; LIVER PROTECTION; LOW DRUG DOSE; MICROALBUMINURIA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITAMIN D DEFICIENCY;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D; VITAMINS;

EID: 63149180995     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0080-4     Document Type: Review

References (55)

1. Centers for Disease Control and Prevention: National diabetes fact sheet general information and national estimates on diabetes in the United States, 2007. Available at http://www.cdc.gov/diabetes/pubs/pdf/ ndfs_2007.pdf. 2007. Accessed August 28, 2008.
2. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352: 213-219.
3. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414: 813-820.
4. Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003, 14: 274-281.
5. Ziyadeh FN: Mediators of diabetTc renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1): S55-S57.
6. Furuta T, Saito T, Ootaka T, et al.: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993, 21: 480-485.
7. LavoieOJL, Sigmund CD: Minireview: overview of the reninangiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144: 2179-2183.
8. Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86: 747-803.
9. Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57: 590-600.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
11. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345: 870-878.
12. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57: 601-606.
13. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10: 2382-2391.
14. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002, 39: 129-134.
15. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265: F477-F486.
16. Vidotti DB, Casarini DE, Cristovam PC, et al.: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286: F1039-F1045.
17. Yoo TH, Li JJ, Kim JJ, et al.: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007, 71: 1019-1027.
18. Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al.: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998, 54: 343-352.
19. Hoffmann S, Podlich D, Hahnel B, et al.: Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004, 15: 1475-1487.
20. Schiffer M, Bitzer M, Roberts IS, et al.: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108: 807-816.
21. Roestenberg P, van Nieuwenhoven FA, Joles JA, et al.: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006, 290: F1344-F1354.
22. Ha H, Yu MR, Choi YJ, et al.: Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002, 13: 894-902.
23. Yamagishi S, Inagaki Y, Okamoto T, et al.: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002, 277: 20309-20315.
24. HolicP MF: Vitamin D: photobiology, metabolism, mechanism of action, and clinical application. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 3. Edited by Favus MJ. Philadelphia: Lippincott-Raven; 1996:74-81.
25. Haussler MR, Whitfield GK, Haussler CA, et al.: The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13: 325-349.
26. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26: 662-687.
27. Li YCA Qiao G, Uskokovic M, et al.: Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89-90: 387-392.
28. Li YC, Kong J, Wei M, et al.: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110: 229-238.
29. Zhou CL, Lu FX, Cao KX, et al.: Calcium-independent and 1,25(OH)(2)D(3)-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008, 74: 170-179.
30. Xiang W, Kong J, Chen S, et al.: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288: E125-E132.
31. Kong J, Qiao G, Zhang Z, et al.: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008 (in press).
32. Yuan W, Pan W, Kong J, et al.: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007, 282: 29821-29830.
33. Qiao G, Kong J, Uskokovic M, Li YC: Analogs of 1alpha,25-dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005, 96: 59-66.
34. Fryer RM, Rakestraw PA, Nakane M, et al.: Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007, 106: P76-p81.
35. Levin A, Bakris GL, Molitch M, et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007, 71: 31-38.
36. Levin A, Li YC: VitaminDD and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005, 68: 1973-1981.
37. Shoben AB, Rudser KD, de Boer IH, et al.: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19: 1613-1619.
38. Shoji T, Shinohara K, Kimoto E, et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004, 19: 179-184.
39. Teng M, Wolf M, Ofsthun MN, et al.: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005, 16: 1115-1125.
40. Kuhlmann A, Haas CS, Gross ML, et al.: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286: F526-F533.
41. Makibayashi K, Tatematsu M, Hirata M, et al.: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001, 158: 1733-1741.
42. Zhang Z, Sun L, Wang Y, et al.: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73: 163-171.
43. Zhang Z, Yuan W, Sun L, et al.: 1,25-Dihydroxyvitamin D(3) targeting of NF-kappaB suppresses high glucoseinduced MCP-1 expression in mesangial cells. Kidney Int 2007, 72: 193-201.
44. Gross JL, de Azevedo MJ, Silveiro SP, et al.: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28: 164-176.
45. Izuhara Y, Nangaku M, Inagi R, et al.: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005, 16: 3631-3641.
46. Eijkelkamp WB, Zhang Z, Remuzzi G, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18: 1540-1546.
47. Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358: 2433-2446.
48. Muller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1: 221-228.
49. Li YC: InhibitiAn of renin: an updated review of the development of renin inhibitors. Curr Opin Investig Drugs 2007, 8: 750-757.
50. Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33: 40-45.
51. Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21: 53-57.
52. Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15: 3126-3133.
53. Zhang Z, Zhang Y, Ning G, et al.: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008 (in press).
54. Shankland SJ: The podocyte's Response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69: 2131-2147.
55. Kawachi H, Miyauchi N, Suzuki K, et al.: Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006, 11: 274-281.